General Information of Drug (ID: DMPIHN6)

Drug Name
AZD5582 Drug Info
Synonyms AZD 5582; AZD-5582
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
49847690
TTD Drug ID
DMPIHN6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT-406 DMVJW0S Squamous head and neck cell carcinom 2D60.0 Phase 3 [2]
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [3]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [3]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [3]
PMID25980951-Compound-44 DMS5896 N. A. N. A. Patented [3]
Drug Name Drug ID Indication ICD 11 Highest Status REF
ASTX660 DMMKW8L Lymphoma 2A80-2A86 Phase 2 [4]
AEG35156 DM2HRYD Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
EMBELIN DMFZO4Y N. A. N. A. Terminated [6]
SM-337 DMOSTP9 Discovery agent N.A. Investigative [7]
SM-131 DMP8VO6 Discovery agent N.A. Investigative [8]
BV-6 DMDTV7A Discovery agent N.A. Investigative [9]
SM-122 DMC7YQE Discovery agent N.A. Investigative [7]
ARPFAQK-FAM DMU70YP Discovery agent N.A. Investigative [6]
AVPIAQKSEK-FAM DMNQ9R4 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 9 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT-406 DMVJW0S Squamous head and neck cell carcinom 2D60.0 Phase 3 [2]
Birinapant DM6PBUM Lymphoma 2A80-2A86 Phase 2 [10]
PMID25980951-Compound-6 DMVSW5N N. A. N. A. Patented [3]
PMID25980951-Compound-27 DMXAH9F N. A. N. A. Patented [3]
PMID25980951-Compound-43 DMTJRCS N. A. N. A. Patented [3]
PMID25980951-Compound-1 DMYPT2H N. A. N. A. Patented [3]
PMID25980951-Compound-44 DMS5896 N. A. N. A. Patented [3]
PMID25980951-Compound-3 DMPSWXU N. A. N. A. Patented [3]
PMID25980951-Compound-4 DM9RZSH N. A. N. A. Patented [3]
PMID25980951-Compound-21 DMIE0MR N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cellular inhibitor of apoptosis 1 (BIRC2) TTQ5LRD BIRC2_HUMAN Antagonist [1]
Cellular inhibitor of apoptosis 2 (BIRC3) TTIRY6K BIRC3_HUMAN Antagonist [1]
XIAP messenger RNA (XIAP mRNA) TTK3WBU XIAP_HUMAN Antagonist [1]

References

1 Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919.
2 Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
3 Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
6 Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40.
7 Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7.
8 Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of ca... J Med Chem. 2008 Dec 11;51(23):7352-5.
9 IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81.
10 cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.